Clinical trials
Lung Cancer Patients clinical trials
Below are recruiting lung cancer patients clinical trials, each written for real people, not researchers. We’re tracking 1,876 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07760012Recruiting
Pet scan with new tracer for solid tumors
This study uses a new imaging tracer, called 68Ga-SorB, during a PET/CT scan to look at tumors. It may help doctors see cancer more clearly. The trial is for adults with certain types of solid tumors (such as melanoma, liver, lung, breast, pancreatic, ovarian, or bile duct cancer) who need a PET/CT scan as part of their care.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05636969Recruiting
Pre-surgery exercise program for lung cancer treatment
This trial looks at whether a “prehabilitation” (guided exercise and fitness preparation) program helps people with non-small cell lung cancer get ready for surgery after starting treatment before surgery. It may help you tolerate treatment and surgery better if you can do the required fitness testing and procedures.
Barcelona, BarcelonaAges 18 years+ - NCT06239194RecruitingPhase 1/Phase 2
MdX2001 for advanced solid tumors
This trial tests a new drug, MDX2001, for people with advanced solid tumors that have spread. The study aims to find the best dose and see how well it works.
Denver, ColoradoAges 18 years+ - NCT06889467Recruiting
Testing leftover fluid from lymph node biopsies to find lung cancer
This trial is for people who are scheduled for a lung cancer biopsy (EBUS-TBNA) because doctors suspect non-small cell lung cancer (NSCLC) has spread to lymph nodes. It will test leftover fluid from the biopsy to see if it improves cancer detection. If your biopsy is negative but you still need surgery to remove lymph nodes, you can help us learn more about this new test.
AshkelonAges 18 years+ - NCT07153055RecruitingPhase 1/Phase 2
Lurbinectedin with osimertinib for transformed small cell lung cancer
This trial tests a combination of two drugs—lurbinectedin and osimertinib—for people whose lung cancer started as EGFR-mutated non-small cell lung cancer but has changed into small cell lung cancer. The goal is to see if this combination can help control the cancer.
Indianapolis, IndianaAges 18 years+ - NCT07652736Recruiting
Tislelizumab for lung cancer in routine care
This study watches how well Tislelizumab works for people with lung cancer when it is used as part of their normal treatment. It does not give you any new medicine or change your care plan.
CórdobaAges 18 years+ - NCT03787056Recruiting
Blood test marker study in many cancer types
This study measures a blood marker called progastrin (at diagnosis and during treatment) to see how well it predicts response or outcomes. It may help doctors choose or monitor treatment more precisely for several cancer types.
BronAges 18 years+ - NCT05537922Recruiting
Study uses data to tailor lung cancer care with immunotherapy
This study collects and analyzes medical information (and sometimes tissue samples) to help personalize treatment plans for advanced non-small-cell lung cancer using immunotherapy. It may help researchers find which people benefit most and how treatment can be better matched to each patient.
Chicago, IllinoisAges 18 years+ - NCT05733000RecruitingPhase 2
CPI-613 plus hydroxychloroquine with chemo for advanced solid tumors
This trial tests a drug called CPI-613 (devimistat) combined with hydroxychloroquine along with either 5-fluorouracil or gemcitabine chemo. It’s for people with advanced cancers that have stopped responding to standard treatments, aiming to shrink tumors and slow cancer growth.
Chicago, IllinoisAges 18 years+ - NCT05778708Recruiting
Tai Chi and aerobic exercise for mood and sleep in late lung cancer
This study tests whether Tai Chi and aerobic exercise can improve clusters of emotional symptoms—like anxiety, low mood, poor sleep, and fatigue—in people with late-stage non-small cell lung cancer. If you have these symptoms and are not already doing regular exercise programs, the trial may offer a structured way to feel better.
Hong KongAges 18 years+ - NCT06026735Recruiting
Lung cancer with brain spread: a surgical study
This trial looks at people with non-small cell lung cancer that has spread to the brain or the membranes around the brain. It aims to learn more about patients who are already scheduled for brain surgery, such as removing a tumor or placing a drain.
TaipeiAges 20–90 - NCT05732974Recruiting
Using a computer tool to find lung cancer relapse risk
This study uses a machine-learning computer method to identify people with early-stage lung cancer who have a higher risk of the cancer coming back after surgery. If you qualify, your information may help researchers improve how doctors predict relapse and plan follow-up care.
ToulouseAges 18 years+ - NCT05550961Recruiting
Real-world study of innovative treatments for lung cancer
This study collects real-world information about people with lung cancer who get newer kinds of cancer drugs. It aims to understand how these innovative therapies work in everyday care and help future research.
MilanAges 18 years+ - NCT04790253Recruiting
Check brain radiation timing or frequent MRI scans for SCLC
This study compares two ways to follow and treat small-cell lung cancer in the brain: preventive brain radiation versus close monitoring with MRI scans and treatment only if needed. It may help people avoid unnecessary brain treatment or choose the safer timing strategy.
GrazAges 18 years+ - NCT06126406RecruitingPhase 1
CEA-targeting CAR-T cell therapy for advanced solid tumors
This trial tests a new immune cell therapy (CAR-T) designed to attack cancer cells that make a protein called CEA. It may be an option for people with advanced colorectal, esophageal, gastric, or pancreatic cancer who have already tried at least two standard treatments.
Wuhu, AnhuiAges 18 years+ - NCT05258448Recruiting
Chemo-radiotherapy for advanced, non-surgical lung cancer
This trial studies treatment that combines chemotherapy and radiation for people with advanced lung cancer that cannot be removed with surgery. It may help improve cure chances for patients who can complete the study tests, including heart scans.
Odense CAges 18 years+ - NCT06168032Recruiting
COVID-19 vaccine for lung cancer patients
This trial is testing how well the COVID-19 vaccine works for people with lung cancer to prevent another infection. It also looks at certain biomarkers in your blood that might help predict your body's immune response.
BeijingAges 18 years+ - NCT06255197Recruiting
Study of lung cancer surgery patients and their outcomes
This study looks at the characteristics, treatments, and results of people who have had surgery to remove lung cancer. It aims to help doctors understand what happens after surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05085028RecruitingPhase 3
Lower-dose pembrolizumab for lung cancer after 6 months
This trial studies whether giving pembrolizumab less often can work just as well for advanced non-small cell lung cancer after you’ve already had 6 months of treatment and are still benefiting. It may help reduce how often you need treatment while keeping cancer control.
BournemouthAges 18 years+ - NCT06128837RecruitingPhase 3
Study of a new drug for recurrent small cell lung cancer
This trial tests a drug called LY01610 for people with small cell lung cancer that has returned after initial chemotherapy. It may offer a new treatment option for those whose cancer progressed within 6 months of their last treatment.
BeijingAges 18 years+ - NCT06032052RecruitingPhase 2
Chemo plus immunotherapy for older adults with metastatic lung cancer
This trial tests a combination of chemotherapy and immunotherapy for people 65 or older with metastatic non-small cell lung cancer that has not been treated before and expresses PD-L1. It aims to see if this treatment can help control the cancer.
Wuhan, HubeiAges 65 years+ - NCT06327594Recruiting
Muscle loss check in lung cancer surgery patients
This study looks at muscle loss (sarcopenia) in people with lung cancer who are about to have surgery. It uses a CT or MRI scan to check your muscle health, which may help doctors better plan your care.
Chengdu, SichuanAges 40–100 - NCT06387017Recruiting
Can blood tests improve lung cancer screening in smokers with artery disease?
This study looks at whether certain blood tests can help find lung cancer early in people who have smoked for a long time and also have artery disease. The goal is to see if adding these tests to current screening methods can better identify those at highest risk.
MarseilleAges 45–80 - NCT03979170Recruiting
Test lung cancer drug response using patient tumor mini-organs
This trial grows “organoids” (mini tumor models) from your lung cancer tissue to see which drug responses are most likely. It may help match future treatments to how your tumor behaves in the lab.
GenevaAges 18 years+
Hear when a new Lung Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer patients?
- Yes. Clin2 currently lists 1,876 recruiting lung cancer patients studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer patients trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer patients trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.